https://orcid.org/0000-0001-8049-3703
References
- Almeleebia TM, Alsayari A, Wahab S. 2022. Pharmacological and clinical efficacy of Picrorhiza kurroa and its secondary metabolites: a comprehensive review. Molecules. 27(23):8316. doi:10.3390/molecules27238316.
- Ayyamperumal S, Dj D, Tallapaneni V, Mohan S, S B, Selvaraj J, Joghee NM, Mjn C. 2021. Molecular docking analysis of α-topoisomerase II with δ-Carboline derivatives as potential anticancer agents. Bioinformation. 17(1):249–265. doi:10.6026/97320630017249.
- Bayram M, Yildirim O, Ozmen RS, Soylu B, Dundar AS, Koksal AR, Akarsu M, Kumbasar A, Tabak O. 2021. Elevation of serum transaminase levels due to favipiravir use in the treatment of COVID-19. Cureus. 13(9):e18166. doi:10.7759/cureus.18166.
- Bilici S, Altuner D, Suleyman Z, Bulut S, Sarigul C, Gulaboglu M, Altindag F, Ozcicek A, Gursul C, Suleyman H, et al. 2023. Favipiravir-induced inflammatory and hydropic degenerative liver injury in rats. Adv Clin Exp Med. 32(8):881–887. doi:10.17219/acem/159089.
- Bisht L, Ram V. 2017. Allopolyherbal formulations and their strategies. J Phytochem Biochem. 1:101.
- Ding L, Jia C, Zhang Y, Wang W, Zhu W, Chen Y, Zhang T. 2019. Baicalin relaxes vascular smooth muscle and lowers blood pressure in spontaneously hypertensive rats. Biomed Pharmacother. 111:325–330. doi:10.1016/j.biopha.2018.12.086.
- Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. 2021. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 102:501–508. doi:10.1016/j.ijid.2020.10.069.
- Kim YH, Jeong DW, Kim YC, Sohn DH, Park ES, Lee HS. 2007. Pharmacokinetics of baicalein, baicalin and wogonin after oral administration of a standardized extract of Scutellaria baicalensis, PF-2405 in rats. Arch Pharm Res. 30(2):260–265. doi:10.1007/BF02977703.
- Kulkarni P, Padmanabhan S. 2022. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19. Biotechnol Lett. 44(7):831–843. doi:10.1007/s10529-022-03259-6.
- Kumar S, Patial V, Soni S, Sharma S, Pratap K, Kumar D, Padwad Y. 2017. Picrorhiza Kurroa enhances β-cell mass proliferation and insulin secretion in Streptozotocin evoked β-cell damage in rats. Front Pharmacol. 8:537. doi:10.3389/fphar.2017.00537.
- Łagocka R, Dziedziejko V, Kłos P, Pawlik A. 2021. Favipiravir in therapy of viral infections. J Clin Med. 10(2):273. doi:10.3390/jcm10020273.
- Li K, Liang Y, Cheng A, Wang Q, Li Y, Wei H, Zhou C, Wan X. 2021. Antiviral properties of baicalin: a concise review. Rev Bras Farmacogn. 31(4):408–419. doi:10.1007/s43450-021-00182-1.
- Liu H, Ye F, Sun Q, Liang H, Li C, Li S, Lu R, Huang B, Tan W, Lai L, et al. 2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. J Enzyme Inhib Med Chem. 36(1):497–503. doi:10.1080/14756366.2021.1873977.
- Misar Wajpeyi S. 2020. Hepatoprotective and hypolipidemic effect of kutaki (Picrorhiza kurroa royle ex benth.) – a review. Int J Res Anal Rev. 6(1):782–788.
- Saifullah M, Yusof YA, Chin NL, Aziz MG. 2016. Physicochemical and flow properties of fruit powder and their effect on the dissolution of fast dissolving fruit powder tablets. Powder Technol. 301:396–404. doi:10.1016/j.powtec.2016.06.035.
- Woolbright BL, Jaeschke H. 2012. Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol. 18(36):4985–4993. doi:10.3748/wjg.v18.i36.4985.
- Yamazaki S, Suzuki T, Sayama M, Nakada TA, Igari H, Ishii I. 2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. J Infect Chemother. 27(2):390–392. doi:10.1016/j.jiac.2020.12.021.
- Zhao Y, Li H, Gao Z, Gong Y, Xu H. 2006. Effects of flavonoids extracted from Scutellaria baicalensis Georgi on hemin-nitrite-H2O2 induced liver injury. Eur J Pharmacol. 536(1-2):192–199. doi:10.1016/j.ejphar.2006.02.045.